Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured over RMB 200 million (USD 27.3 million) in a Series B financing round. The round was co-led by Yuexiu Industrial Investment Fund and CCB PE, with significant contributions from Tencent Investment, Eight Roads, and Alwin Capital. The funds will be directed towards the research and development, manufacturing, and commercialization of Sonosemi’s core products.
Investment and Company Background
Founded in 2020, Sonosemi Medical has quickly established itself as a leader in the field of vascular intervention, offering a range of products including coronary artery intravascular shock wave therapy systems, peripheral artery intravascular shock wave therapy systems, intracardiac ultrasound imaging systems, and intravascular ultrasound devices.
Product Portfolio and Market Impact
Sonosemi’s product portfolio addresses various vascular conditions, providing innovative solutions for coronary and peripheral artery diseases. The company’s intracardiac ultrasound imaging system and intravascular ultrasound devices are designed to enhance diagnostic capabilities and treatment outcomes in cardiovascular interventions.-Fineline Info & Tech
